For the Inventor, By the Inventor

Enter assignee name

South San Francisco, CA, United States of America

Cor Therapeutics, Inc.

USPTO Granted Patents = 92

CIPO Patents = 3

Trademarks = 1

Forward Citations = 910

Loading Chart...

Loading Chart...

44 inventors (with patents filed for the assignee):

Robert M Scarborough (59 out of 153 patents)

David Lawrence Wolf (31 out of 33 patents)

Bing-Yan Zhu (20 out of 78 patents)

4. Israel F Charo (20 out of 23 patents)

5. Uma Sinha (10 out of 32 patents)

6. Charles K Marlowe (9 out of 22 patents)

7. Neill A Giese (6 out of 11 patents)

8. David R Phillips (6 out of 28 patents)

9. Johan Sundelin (6 out of 8 patents)

10. Shaun R Coughlin (5 out of 21 patents)

11. Alan M Laibelman (5 out of 6 patents)

12. Nathalie Lokker (5 out of 5 patents)

13. Larry J Fretto (4 out of 7 patents)

14. Robert King (4 out of 4 patents)

15. Ting Su (3 out of 9 patents)

Core Competencies:

Factor Xa Inhibitors

Selective Factor Xa Inhibitors

Ketoheterocyclic Inhibitors

Integrin-Mediated Signal Transduction

Nucleic Acids Encoding C140 Receptor

Thrombin Receptor Antagonists

Platelet Aggregation Inhibitors

Agents Affecting Thrombosis

Bap-1 Proteins

Glycosylation-Mediated Inhibition

Recombinant Thrombin Receptor

Pharmaceutical Compositions

92 patents: Sort by Forward Citations

1. 6399627 - Inhibitors of factor Xa (2002-06-04),

2. 6376515 - Benzamides and related inhibitors of factor Xa (2002-04-23),

3. 6369080 - Selective factor Xa inhibitors (2002-04-09),

4. 6369063 - Selective factor Xa inhibitors (2002-04-09),

5. 6333321 - Selective factor Xa inhibitors (2001-12-25),

6. 6297026 - Nucleic acids encoding the C140 receptor (2001-10-02),

7. 6262047 - Selective factor Xa inhibitors (2001-07-17),

8. 6245743 - Inhibitors of factor Xa (2001-06-12),

9. 6228854 - Selective factor Xa inhibitors (2001-05-08),

10. 6218382 - Selective factor Xa inhibitors (2001-04-17),

11. 6211183 - Selective factor Xa inhibitors (2001-04-03),

12. 6211154 - Ketoheterocyclic inhibitors of factor Xa (2001-04-03),

13. 6210913 - Modulation of integrin-mediated signal transduction (2001-04-03),

14. 6204268 - Selective factor Xa inhibitors (2001-03-20),

15. 6197748 - Ketoheterocyclic inhibitors of factor Xa (2001-03-06),

Cor Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of drugs for the treatment of cardiovascular diseases. With a commitment to improving patient outcomes, Cor Therapeutics conducts extensive research and development to discover innovative therapies. The company's website provides comprehensive information about their products, pipeline, and corporate initiatives.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

92 Patents

#13 in South San Francisco, CA

#933 in California

#3,915 in US

#8,094 in the World

South San Francisco, CA, United States of America

Cor Therapeutics, Inc.

Forward Citations = 910

44 inventors:

Robert M Scarborough (59 out of 153 patents)

David Lawrence Wolf (31 out of 33 patents)

Bing-Yan Zhu (20 out of 78 patents)

4. Israel F Charo (20 out of 23 patents)

5. Uma Sinha (10 out of 32 patents)

Please report any incorrect information to support@idiyas.com

Loading…